

Albaugh Inc.

OFFICE

121 N.E. 18th St.
Ankeny, Iowa 50021

Phone: 515-964-9444
Toll Free: 800-247-8013
Fax: 515-964-7813

PLANT

4900 Packers Avenue
St. Joseph, MO 64504

Phone: 816-238-3377
FAX: 816-238-3938

83002

40990000003

Bla-023

lpp

PROPRIETARY AND CONFIDENTIAL

January 11, 1999

VIA CERTIFIED MAIL RETURN RECEIPT REQUESTED

Document Control Office
Mail Code 7407
Office of Pollution Prevention and Toxics
U.S. Environmental Protection Agency
Room G009
401 M Street, S.W.
Washington, D.C. 20460

ATTN: TSCA § 4

Dear Sir or Madam:

This letter is submitted pursuant to 40 C.F.R. §§ 766.55(a)(1) and 790.45 to notify the Environment Protection Agency of Albaugh, Inc.'s intent to conduct testing of *material redacted* under 40 C.F.R. Part 766. Pursuant to 40 C.F.R. § 790.45, we provide the following information:

1. The test rule is 40 C.F.R. Part 766, Dibenzo-Paradoxins Dibenzo-furans.
2. The firm that will be sponsoring the tests is:

Albaugh, Inc.
121 N.E. 18th Street
Ankeny, IA 50021
515/964-9444.
3. The appropriate individual to contact for further information is Glen O'Brien, Business Manager, at the above address and telephone number.
4. There is no testing consortium.
5. The testing requirements for which Albaugh intends to conduct tests are all requirements set forth in 40 C.F.R. Part 766 applicable to *material redacted*.

RECEIVED

JAN 28 1999

CTB CCD

RECEIVED
OPT CHIC

99 JAN 19 PM 3:14

RECEIVED
OPT CHIC

99 JAN 25 PM 12:20

COMPANY SANITIZED
CONTAINS NO CBI

January 11, 1999


6. The test substance that Albaugh intends to use in each of the tests is
material redacted

Albaugh first imported the test substance on November 16, 1998. Therefore, this notice of intent to conduct testing is timely under 40 C.F.R. § 766.35(a)(1)(ii).

Albaugh hereby claims business confidentiality for the identity of the test substance covered by this notice of intent to conduct testing; a redacted copy of this letter is enclosed for use by the EPA. Albaugh acknowledges that "health and safety data" regarding the test substance as defined in 40 C.F.R. § 2.306(a)(3) are not eligible for confidential treatment.

Please let us know if you require further information.

Sincerely,



Glen F. O'Brien
Business Manager